Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

HPV Vaccine Working, Says CDC

By Drug Discovery Trends Editor | February 26, 2016

The HPV vaccine, introduced about a decade ago, is working at a population level to beat back the most common sexually transmitted infection, according to a new CDC study.

The study analyzed some 5,000 young females – and found a dramatic reduction in key strains of the human papillomavirus,according to the results, in the journal Pediatrics.

But immunization rates still remain low nationwide, they added.

“Within six years of vaccine introduction, there was a 64 percent decreased in (four types) of HPV prevalence among females aged 14 to 19 years and a 34 percent decrease among those aged 20 to 24 years,” conclude the scientists. “This finding extends previous observations of population impact in the United States and demonstrates the first national evidence of impact among females in their 20s.”

The scientists took swabs from 3,325 females aged 14 to 34 in the pre-vaccine era, the years 2003 to 2006. They compared the prevalence of the strains of the virus with 2,473 females in the same age range from 2009 to 2012, the vaccine era.

The reduction in the virus at the samples population was even more startling than had been expected, they said.

Caveats to the success exist, however. The vaccine only covers the most dangerous and common strains. Prevalence of any HPV strain actually went up in the vaccine era – from 54.4 percent to 58 percent.

National immunization rates are also below 40 percent for teenage girls, partly due to parental resistance. The controversy since the CDC recommended the vaccine for girls in 2006 has focused mostly on adults’ reluctance to consider their children becoming sexually active, according to multiple reports. But there have also been debunked rumors of the vaccine carrying its own dangers, according to the American Cancer Society.

HPV is the cause of around 60 percent of all cervical cancers in the U.S. – a disease which strikes about 12,000 U.S. women a year and kills around 4,000.

Since 2011, the CDC has also recommended the HPV vaccine for boys. The virus strains that are carcinogenic can also cause cancers of the vulva, penis, anus and throat, according to the CDC.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE